PCSK9 and hyperlipidemia: Therefore, together with statin therapy, anti-PCSK9 antibodies are currently used for the clinical treatment of hyperlipidemia to decrease the risk of residual cardiovascular diseases (CVDs), a leading cause of death in humans.